Log in / Register
Home arrow Environment arrow Inflammatory Disorders of the Nervous System: Pathogenesis, Immunology, and Clinical Management


Autoimmune encephalitis has different immunologic mechanisms, clinical manifestations, and therapeutic outcomes. It can be divided into two categories: antibodies against intracellular antigens or antibodies against neuronal surface/synaptic antigens. More than half of patients with autoimmune encephalitis present with symptoms of limbic encephalopathy including memory deficits, altered mental status, seizures, and neuropsychiatric syndrome. Patients with the clinical presentation of encephalitis should have a complete workup including neuroimaging, EEG, lumbar puncture, and serologic testing. Other etiologies of encephalitis are more common and should be excluded. Patients often respond favorably to immunotherapy. Delay in diagnosis and treatment has been associated with a worse prognosis.


  • 1. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77:179-89.
  • 2. Tuzun E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist. 2007;13:261-71.
  • 3. Greenfield JG. Subacute spino-cerebellar degeneration occurring in elderly patients. Brain. 1934;57:161-76.
  • 4. Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry. 1948;11:73-87.
  • 5. Henson RA, Russell DS, Wilkinson M. Carcinomatous neuropathy and myopathy a clinical and pathological study. Brain. 1954;77:82-121.
  • 6. Charatan FB, Brierley JB. Mental disorder associated with primary lung carcinoma. Br Med J. 1956;1:765-8.
  • 7. Corsellis JA, Goldberg GJ, Norton AR. ‘Limbic encephalitis’ and its association with carcinoma. Brain. 1968;91:481-96.
  • 8. Buckley C et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol. 2001;50:73-8.
  • 9. Ances BM et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005;128:1764-77.
  • 10. Dalmau J et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091-8.
  • 11. Dalmau J et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25-36.
  • 12. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci. 2007;8:413-26.
  • 13. Gable MS et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis. 2009;28:1421-9.
  • 14. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California encephalitis project. Clin Infect Dis. 2012;54:899-904.
  • 15. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63-74.
  • 16. Gozzard P et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study. Neurology. 2015;85:235-9.
  • 17. Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76:795-800.
  • 18. Graus F et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138-48.
  • 19. Sillevis Smitt P et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002;249:745-53.
  • 20. Gultekin SH et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481-94.
  • 21. Honnorat J et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology. 2013;80:2226-32.
  • 22. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encepha- lomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore). 1992;71:59-72.
  • 23. Shams’ili S et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126:1409-18.
  • 24. Saiz A et al. Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry. 2009;80:404-7.
  • 25. Luque FA et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29:241-51.
  • 26. Kim H, Lim Y, Kim K-K. Anti-ri-antibody-associated paraneoplastic syndrome in a man with breast cancer showing a reversible pontine lesion on MRI. J Clin Neurol. 2009;5:151-2.
  • 27. Greenlee JE et al. Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: detection of Yo antigen in tumor tissue and fall in antibody titers following tumor removal. Ann Neurol. 1999;45:805-9.
  • 28. Voltz R et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999;340:1788-95.
  • 29. Dalmau J et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127:1831-44.
  • 30. Waragai M et al. Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy. J Neurol Neurosurg Psychiatry. 2006;77:111-3.
  • 31. Saiz A et al. Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry. 1999;66:214-7.
  • 32. Antoine JC et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol. 1999;56:172-7.
  • 33. David C, McPherson PS, Mundigl O, de Camilli P. A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc Natl Acad Sci U S A. 1996;93:331-5.
  • 34. Yu Z et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49:146-54.
  • 35. Vernino S et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol. 2002;51:625-30.
  • 36. Knudsen A et al. Antibodies to CRMP3-4 associated with limbic encephalitis and thymoma. Clin Exp Immunol. 2007;149:16-22.
  • 37. Tuzun E, Rossi JE, Karner SF, Centurion AF, Dalmau J. Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. J Neuroimmunol. 2007;186:177-80.
  • 38. Sabater L, Gomez-Choco M, Saiz A, Graus F. BR serine/threonine kinase 2: a new autoantigen in paraneoplastic limbic encephalitis. J Neuroimmunol. 2005;170:186-90.
  • 39. Titulaer MJ et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157-65.
  • 40. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013;70:1133-9.
  • 41. Hacohen Y et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry. 2013;84:748-55.
  • 42. Iizuka T et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology. 2008;70:504-11.
  • 43. Shimazaki H, Ando Y, Nakano I, Dalmau J. Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus. J Neurol Neurosurg Psychiatry. 2007;78:324-5.
  • 44. Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and ‘optic neuritis’: paraneoplastic effects of bronchial carcinoma. Neurology. 1984;34:788-91.
  • 45. Lebas A, Husson B, Didelot A, Honnorat J, Tardieu M. Expanding spectrum of encephalitis with NMDA receptor antibodies in young children. J Child Neurol. 2010;25:742-5.
  • 46. Wingfield T et al. Autoimmune encephalitis: a case series and comprehensive review of the literature. QJM. 2011;104:921-31.
  • 47. Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology. 2011;76:1355-7.
  • 48. Irani SR et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69:892-900.
  • 49. Sen A et al. Pathognomonic seizures in limbic encephalitis associated with anti-LGI1 antibodies. Lancet (London/England). 2014;383:2018.
  • 50. Tofaris GK et al. Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology. 2012;79:195-6.
  • 51. Fukata Y et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci U S A. 2010;107:3799-804.
  • 52. Lai M et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9:776-85.
  • 53. Hoftberger R et al. Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. Neurology. 2015;84:2403-12.
  • 54. Klein CJ et al. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol. 2013;70:229-34.
  • 55. Irani SR et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72:241-55.
  • 56. Petit-Pedrol M et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13:276-86.
  • 57. Hoftberger R et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81:1500-6.
  • 58. Sabater L et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575-86.
  • 59. Suleiman J et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology. 2011;76:1252-5.
  • 60. Cornelius JR et al. Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol. 2011;68:733-8.
  • 61. Hutchinson M et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008;71:1291-2.
  • 62. Mas N et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry. 2011;82:1399-401.
  • 63. Clerinx K et al. Progressive encephalomyelitis with rigidity and myoclonus: resolution after thymectomy. Neurology. 2011;76:303-4.
  • 64. Boronat A et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013;73:120-8.
  • 65. Tobin WO et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797-803.
  • 66. Pruss H et al. Limbic encephalitis with mGluR5 antibodies and immunotherapy-responsive prosopagnosia. Neurology. 2014;83:1384-6.
  • 67. Lancaster E et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011;77:1698-701.
  • 68. Johnson N, Henry C, Fessler AJ, Dalmau J. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology. 2010;75:1480-2.
  • 69. Graus F et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135-40.
  • 70. Flanagan EP et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc. 2010;85:881-97.
  • 71. Geschwind MD et al. Voltage-gated potassium channel autoimmunity mimicking creutzfeldt- jakob disease. Arch Neurol. 2008;65:1341-6.
  • 72. Florance NR et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11-8.
  • 73. Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic Limbic encephalitis. Mayo Clin Proc. 2003;78:1363-8.
  • 74. Gresa-Arribas N et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13:167-77.
Found a mistake? Please highlight the word and press Shift + Enter  
< Prev   CONTENTS   Next >
Business & Finance
Computer Science
Language & Literature
Political science